Globeflex Capital L P Makes New Investment in Agenus Inc. $AGEN

Globeflex Capital L P purchased a new position in Agenus Inc. (NASDAQ:AGEN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 418,581 shares of the biotechnology company’s stock, valued at approximately $1,281,000.

Other large investors also recently modified their holdings of the company. LPL Financial LLC raised its stake in shares of Agenus by 20.3% in the fourth quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock worth $73,000 after buying an additional 3,943 shares during the period. Sherbrooke Park Advisers LLC bought a new position in shares of Agenus during the 3rd quarter valued at approximately $64,000. Acadian Asset Management LLC purchased a new stake in Agenus in the 1st quarter worth approximately $58,000. Jump Financial LLC purchased a new stake in Agenus in the 2nd quarter worth approximately $55,000. Finally, Quadrature Capital Ltd purchased a new position in Agenus during the fourth quarter valued at approximately $54,000. Institutional investors own 61.46% of the company’s stock.

Wall Street Analyst Weigh In

AGEN has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. B. Riley Financial reissued a “buy” rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Weiss Ratings cut shares of Agenus from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday. Zacks Research cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $19.50.

Agenus Price Performance

AGEN stock opened at $7.67 on Tuesday. The business has a 50-day moving average price of $5.38 and a 200 day moving average price of $4.15. The company has a market capitalization of $345.30 million, a P/E ratio of 2.97 and a beta of 1.41. Agenus Inc. has a 1-year low of $2.71 and a 1-year high of $8.85.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.The firm had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million. On average, analysts anticipate that Agenus Inc. will post -0.28 earnings per share for the current fiscal year.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.